Rebecca Gelman is involved in collaborative research on cancer and AIDS. She is coordinator of biostatistics collaboration at the Dana-Farber Cancer Institute, where she primarily works on breast cancer clinical trials, breast cancer screening studies, pathology studies, tumor marker studies, and immunogenetics. She is the coordinating statistician for the Harvard Collaborative Oncology Group, which involves cancer clinical trials and epidemiology studies at eight hospitals.
Her primary appointment is in the Radiation Oncology department of Harvard Medical School, where she works on breast cancer, prostate cancer and multiple myeloma studies. Dr. Gelman is section head for the Immunology Committee of the AIDS Clinical Trial Group, and serves on the Flow Advisory Committee of the NIAID. She works on clinical trials of immune-based therapies, runs the national program on flow cytometry quality assessment, and does research on the sources of variation and prognostic/surrog! ate value of immunology tests.
Dr. Gelman's statistical interests reflect her collaborative activities. She is currently involved in:
- proposing new methods for analysis of cancer screening trials,
- quantitating the value of quality assessment programs in prognostic and surrogate factor studies,
- comparing different methods of estimating confidence intervals for coefficient of variation, and
- developing competing risk models for long-term effects of chemotherapy and radiation.
Dr. Gelman received her PhD in statistics from the State University of New York, Buffalo, in 1978. In the same year, she joined the Department of Biostatistics at Harvard School of Public Health and DFCI, and in 1990, the Department of Radiation Oncology at Harvard Medical School. She is associate director of the Biostatistics Core of the Dana-Farber/Harvard Cancer Center, principal investigator of the Biostatistics Core of the Harvard Center for AIDS Research, and chief statistician for the National Institute of Allergy and Infectious Diseases (NIAID) Division of AIDS Immunology Laboratory Quality Assessment Program. She is the only statistician member of the Flow Advisory Committee to the NIAID.
Rath MG, Masciari S, Gelman R, Miron A, Miron P, Foley K, Richardson AL, Krop IE, Verselis SJ, Dillon DA, Garber JE. Prevalence of germline TP53 mutations in HER2+ breast cancer patients. Breast Cancer Res Treat. 2013 May;139(1):193-8.
Mayer EL, Isakoff SJ, Klement G, Downing SR, Chen WY, Hannagan K, Gelman R, Winer EP, Burstein HJ. Combination antiangiogenic therapy in advanced breast cancer: a phase 1 trial of vandetanib, a VEGFR inhibitor, and metronomic chemotherapy, with correlative platelet proteomics. Breast Cancer Res Treat. 2012 Nov;136(1):169-78.
Hammond SP, Gagne LS, Stock SR, Marty FM, Gelman RS, Marasco WA, Poritz MA, Baden LR. Respiratory virus detection in immunocompromised patients with FilmArray respiratory panel compared to conventional methods. J Clin Microbiol.2012 Oct;50(10):3216-21.
Hellmann I, Lim SY, Gelman RS, Letvin NL. Association of activating KIR copy number variation of NK cells with containment of SIV replication in rhesus monkeys. PLoS Pathog. 2011 Dec;7(12):e1002436. doi: 10.1371/journal.ppat.1002436. Epub 2011 Dec 15. Erratum in: PLoS Pathog. 2012 Sep;8(9).
Freedman RA, Bullitt E, Sun L, Gelman R, Harris G, Ligibel JA, Krop IE,
Partridge AH, Eisenberg E, Winer EP, Lin NU. A phase II study of sagopilone (ZK219477; ZK-EPO) in patients with breast cancer and brain metastases. Clin Breast Cancer. 2011 Dec;11(6):376-83.
Letvin NL, Rao SS, Montefiori DC, Seaman MS, Sun Y, Lim SY, Yeh WW, Asmal M, Gelman RS, Shen L, Whitney JB, Seoighe C, Lacerda M, Keating S, Norris PJ, Hudgens MG, Gilbert PB, Buzby AP, Mach LV, Zhang J, Balachandran H, Shaw GM, Schmidt SD, Todd JP, Dodson A, Mascola JR, Nabel GJ. Immune and Genetic Correlates of Vaccine Protection Against Mucosal Infection by SIV in Monkeys. Sci Transl Med. 2011 May 4;3(81):81ra36.
Lim SY, Chan T, Gelman RS, Whitney JB, O'Brien KL, Barouch DH, Goldstein DB, Haynes BF, Letvin NL. Contributions of Mamu-A*01 status and TRIM5 allele expression, but not CCL3L copy number variation, to the control of SIVmac251 replication in Indian-origin rhesus monkeys. PLoS Genet. 2010 Jun 24;6(6):e1000997.
Miron A, Varadi M, Carrasco D, Li H, Luongo L, Kim HJ, Park SY, Cho EY, Lewis G, Kehoe S, Iglehart JD, Dillon D, Allred DC, Macconaill L, Gelman R, Polyak K. PIK3CA mutations in in situ and invasive breast carcinomas. Cancer Res. 2010 Jul 15;70(14):5674-8.
Chen RC, Mamon HJ, Chen YH, Gelman RS, Suh WW, Talcott JA, Clark JW, Hong TS. Patient-reported acute gastrointestinal symptoms during concurrent chemoradiation treatment for rectal cancer. Cancer. 2010 Apr 15;116(8):1879-86.
Tung N, Wang Y, Collins LC, Kaplan J, Li H, Gelman R, Comander AH, Gallagher B, Fetten K, Krag K, Stoeckert KA, Legare RD, Sgroi D, Ryan PD, Garber JE, Schnitt SJ. Estrogen receptor positive breast cancers in BRCA1 mutation carriers: clinical risk factors and pathologic features. Breast Cancer Res. 2010;12(1):R12.